The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...

However, Eli Lilly is gaining momentum, and expects significant catalysts that could send its stock price soaring in 2025.

The combination met its primary endpoint of percent weight loss following an 8-week treatment period.

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

The data also showed that low dose MC4R agonist bremelanotide stopped the rapid weight regain seen after ending GLP-1/GIP tirzepatide treatment." Topline data results from the study were highly ...

while its dual GLP-1/GIP agonist tirzepatide was approved for diabetes in May and for obesity just last week. Outside China, the tirzepatide products are known as Mounjaro and Zepbound ...

The new move comes as Eli Lilly has also taken action against compounders making copies of tirzepatide, its GLP-1 and GIP agonist sold as Mounjaro for diabetes and Zepbound for obesity in the US.

Several global studies, including the widely cited STEP 1 trial, have shown that discontinuing weight-loss medication often ...